MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Marinus Pharmaceuticals, Inc. (the “Company”) issued a press release on October 31, 2017 announcing its financial results for the quarter ended September 30, 2017.A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information furnished to this Item 2.02 shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.

Item 2.02. Financial Statements and Exhibits.

2


MARINUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 mrns_Current folio_Exhibit991         Exhibit 99.1   Marinus Pharmaceuticals PROVIDES business UPDATE and reports third quarter 2017 financial results     RADNOR,…
To view the full exhibit click here

About MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.